Jacqueline Kosecoff
TRINET GROUPAbout Jacqueline Kosecoff
Dr. Jacqueline Kosecoff, age 75, has served as an independent director of TriNet since January 2020; she is Managing Partner at Moriah Partners (since March 2012) and a senior advisor to Warburg Pincus (since March 2012), bringing deep healthcare operating and board experience. She holds a B.A. (UCLA), an M.S. in Applied Mathematics (Brown), and a doctorate from UCLA; her board tenure and healthcare/PE background position her as a governance voice on human capital and risk at TriNet . TriNet’s Board affirms all non‑employee directors (including Dr. Kosecoff) are independent under NYSE rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sealed Air Corporation (public) | Director | May 2005 – May 2021 | Long-tenured public board service in industrials |
| GoodRx (public) | Director | May 2016 – June 2023 | Healthcare/technology governance exposure |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Houlihan Lokey (public) | Director | Since June 2016 | Current public company directorship |
| Alignment Healthcare (public) | Director | Since March 2017 | Current public company directorship |
| STERIS Corporation (public) | Director | Since October 2003 | Current public company directorship |
| Moriah Partners | Managing Partner | Since March 2012 | VC/PE investing leadership |
| Warburg Pincus | Senior Advisor | Since March 2012 | Private equity advisory role |
| Independent Living Systems (private) | Director | Since Apr 2013 | Healthcare services |
| InformedDNA (private) | Director | Since Apr 2020 | Healthcare services |
| Iris Telehealth (private) | Director | Since Jul 2021 | Behavioral health |
| Alegeus Technologies (private) | Director | Since Aug 2021 | Health benefits technology |
| Maxor (private) | Director | Since Mar 2023 | Pharmacy services |
| Intelligent Medical Objections (private) | Director | Since Oct 2023 | Health tech |
Board Governance
- Committee assignments: Member, Compensation & Human Capital Management (CHCM); Member, Risk Committee .
- Independence: Independent under NYSE rules; only the CEO is non‑independent .
- Attendance: The Board met 6 times in 2024; each director attended at least 75% of Board and relevant committee meetings; non‑management directors held 5 executive sessions, chaired by the independent Board Chair .
- Committee activity context: CHCM met 5 times in 2024; Risk met 4 times in 2024 .
Fixed Compensation
| Component | Amount/Policy | 2024 Detail |
|---|---|---|
| Board annual cash retainer (non‑chair) | $60,000 policy amount | Included in Dr. Kosecoff’s $90,000 total cash fees |
| Committee retainers (member) | CHCM: $15,000; Risk: $10,000; Nominating: $10,000; Finance & Audit: $15,000 | Implied within her $90,000 cash total (specific committee cash breakout not separately disclosed) |
- 2024 non‑employee director cash and equity received by Dr. Kosecoff: $90,000 cash; $215,080 stock awards; total $305,080 .
- Policy note: Annual director RSU grant fair value $215,000 (Board Chair $335,000); vests in full by the next annual meeting/12‑month anniversary; eligible to vest upon change in control .
Performance Compensation
| Equity Element | Grant Mechanism | Vesting | 2024 Amount |
|---|---|---|---|
| Annual RSU | Fixed-value RSUs ($215,000 policy) granted at first Board meeting each calendar year | Vests in full on the earlier of 12‑month anniversary or prior to next annual meeting; accelerates upon change in control | $215,080 grant-date fair value in 2024 |
Directors do not receive performance-based options/PSUs; compensation is structured as cash retainers plus time‑based RSUs under the non‑employee director policy .
Other Directorships & Interlocks
| Company | Type | Overlap/Interlock at TriNet |
|---|---|---|
| Alignment Healthcare (public) | Dr. Kosecoff – Director since Mar 2017 | Interlock: TriNet Board Chair David C. Hodgson also serves on Alignment Healthcare’s board since May 2024 . |
- No related‑party transactions were disclosed involving Dr. Kosecoff. Related‑party items disclosed for other directors/entities in 2024 included Atairos (customer), SoundThinking (customer, CEO is director Ralph Clark), and Cigna (vendor, executive is director Brian Evanko) — none involve Dr. Kosecoff .
Expertise & Qualifications
- 30+ years in healthcare industry leadership and public company board service; VC/PE investing and advisory roles (Moriah Partners; Warburg Pincus) .
- Academic credentials: B.A. UCLA; M.S. Applied Mathematics (Brown); doctorate (UCLA) .
- Governance alignment with CHCM and Risk oversight areas at TriNet (committee memberships) .
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Total beneficial ownership (shares) | 14,358 | Includes 12,358 held by Robert H. Brook and Jacqueline B. Kosecoff Family Trust (shared voting/investment power) and 2,000 RSUs issuable within 60 days of Mar 28, 2025 . |
| Ownership % of outstanding | <1% | Less than one percent of 48,397,519 shares outstanding as of Mar 28, 2025 . |
| Unvested director RSUs (12/31/2024) | 2,000 | Each current non‑employee director (except two noted) held 2,000 unvested RSUs at year‑end; applies to Dr. Kosecoff . |
| Stock ownership guideline | 500% of annual cash retainer for directors | Applies to non‑employee directors; unvested/ unexercised awards excluded from compliance calculation . |
| Guideline compliance status | Met or on track within required timeframe | As of Dec 31, 2024, all directors had met or were expected to meet their requirements by deadlines . |
| Hedging/pledging | Prohibited | No pledging, hedging, short sales, or derivatives allowed for directors . |
Governance Assessment
- Strengths: Independent director; active on CHCM (pay, HCM, succession) and Risk committees, aligning her healthcare/PE background with oversight of incentives, culture, and enterprise risk; Board/committee attendance thresholds met; director pay structure is standard (cash + time‑based RSUs) with clear vesting and change‑in‑control treatment; robust ownership guidelines and insider‑trading restrictions; CHCM uses an independent consultant (Meridian) and maintains a Dodd‑Frank compliant clawback .
- Potential watch items: Board interlock with Alignment Healthcare via the Board Chair could merit monitoring for information flow or perceived influence, though no related‑party transactions are disclosed for Dr. Kosecoff; related‑party transactions disclosed for other directors/entities (Atairos, SoundThinking, Cigna) underscore the importance of continued Finance & Audit oversight of conflicts management .
- Shareholder sentiment context: Say‑on‑pay received ~98% support in 2024, signaling strong investor confidence in compensation governance (relevant to CHCM oversight) .
RED FLAGS (none specific to Dr. Kosecoff in disclosed filings): No hedging/pledging; no disclosed related‑party transactions; attendance thresholds met; director compensation within policy limits .